Business
Presentation at Jefferies Healthcare Conference
Presentation at Jefferies Healthcare Conference.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 0722H Allergy Therapeutics PLC 12 November 2018 \n\n \n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nAllergy Therapeutics to present at Jefferies 2018 London Healthcare Conference\n \n12 November 2018 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Manuel Llobet, CEO, and Nick Wykeman, CFO, will attend the Jefferies Healthcare Conference in London on Wednesday 14 November 2018. \n \nNick Wykeman, CFO, will lead an investor presentation at 15.20 GMT on Wednesday 14 November.\n \n \nFor further information, please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\nNick Wykeman, Chief Financial Officer\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Emma Earl, Corporate Finance\nErik Anderson, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser\[email protected]\n \nNotes for editors:\nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.\n \nFormed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com. \n \n \n \n\nThis information is provided by RNS, the news service of the Lon...